Nevro Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Nevro is de winst gegroeid met een gemiddeld jaarlijks percentage van 11.2%, terwijl de Medical Equipment industrie de winst jaarlijks groeide met 12%. De inkomsten zijn gegroeid met een gemiddelde van 2.9% per jaar.

Belangrijke informatie

11.2%

Groei van de winst

14.6%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie	8.9%
Inkomstengroei	2.9%
Rendement op eigen vermogen	-25.3%
Nettomarge	-16.5%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Little Excitement Around Nevro Corp.'s (NYSE:NVRO) Revenues As Shares Take 34% Pounding

Aug 11

Nevro: Not Having My Back

Aug 09

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Jul 16

Nevro Corp. (NYSE:NVRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

May 01

Opbrengsten en kosten

Hoe Nevro geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NYSE:NVRO Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	419	-69	314	52
30 Jun 24	426	-77	327	55
31 Mar 24	431	-83	337	54
31 Dec 23	425	-92	335	54
30 Sep 23	423	-102	335	56
30 Jun 23	419	3	332	56
31 Mar 23	415	2	329	55
31 Dec 22	406	3	322	53
30 Sep 22	395	-8	324	52
30 Jun 22	388	-140	325	49
31 Mar 22	386	-136	315	49
31 Dec 21	387	-131	309	48
30 Sep 21	394	-108	294	47
30 Jun 21	409	-68	283	46
31 Mar 21	363	-88	269	45
31 Dec 20	362	-83	267	46
30 Sep 20	367	-90	276	51
30 Jun 20	358	-98	280	53
31 Mar 20	396	-84	296	57
31 Dec 19	390	-104	306	59
30 Sep 19	384	-100	301	56
30 Jun 19	379	-93	292	55
31 Mar 19	382	-76	281	52
31 Dec 18	387	-49	267	48
30 Sep 18	377	-44	239	45
30 Jun 18	364	-39	228	42
31 Mar 18	346	-40	218	40
31 Dec 17	327	-37	220	38
30 Sep 17	299	-42	202	39
30 Jun 17	278	-40	184	37
31 Mar 17	255	-37	165	36
31 Dec 16	229	-32	142	34
30 Sep 16	191	-36	126	28
30 Jun 16	146	-52	112	26
31 Mar 16	102	-63	98	23
31 Dec 15	70	-67	82	21
30 Sep 15	46	-62	64	20
30 Jun 15	39	-50	49	20
31 Mar 15	36	-38	37	20
31 Dec 14	33	-31	30	20
30 Sep 14	29	-29	26	20
30 Jun 14	27	-26	24	19
31 Mar 14	25	-26	21	19
31 Dec 13	24	-26	19	20

Kwaliteitswinsten: NVRO is momenteel verliesgevend.

Groeiende winstmarge: NVRO is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: NVRO is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 11.2% per jaar verminderd.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van NVRO over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: NVRO is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Medical Equipment industrie ( 10.4% ).

Rendement op eigen vermogen

Hoge ROE: NVRO heeft een negatief Return on Equity ( -25.33% ), omdat het momenteel verliesgevend is.

Nevro Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Nevro Corp. to Report Q3, 2024 Results on Nov 11, 2024

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Nevro Corp. to Report Q2, 2024 Results on Aug 06, 2024

Nevro Corp. to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Recent updates

Nevro Corp. Announces the Publication of New Data in Medical Devices

Consensus EPS estimates upgraded to US$2.42 loss

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Nevro Corp. Reaffirms Earnings Guidance for the Year 2024

Nevro Corp. Announces New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy

Nevro Corp. to Report Q3, 2024 Results on Nov 11, 2024

Consensus EPS estimates fall by 21%

Little Excitement Around Nevro Corp.'s (NYSE:NVRO) Revenues As Shares Take 34% Pounding

Nevro: Not Having My Back

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 25% to US$11.07

Nevro Revises Earnings Guidance for the Full Year 2024

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Nevro Corp. to Report Q2, 2024 Results on Aug 06, 2024

Consensus EPS estimates upgraded to US$2.31 loss

Price target decreased by 12% to US$16.63

Nevro Corp. Provides Earnings Guidance for the Second Quarter Ending June 30, 2024 and Revises Earnings Guidance for the Full Year Ending December 31, 2024

Nevro Corp. (NYSE:NVRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

Nevro Corp. to Report Q1, 2024 Results on May 07, 2024

New minor risk - Shareholder dilution

Nevro Corp., Annual General Meeting, May 23, 2024

Price target decreased by 9.5% to US$19.40

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Full year 2023 earnings: EPS exceeds analyst expectations

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Nevro Corp. to Report Q4, 2023 Results on Feb 21, 2024

There Is A Reason Nevro Corp.'s (NYSE:NVRO) Price Is Undemanding

Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Nevro Corp. Increases Revenue Guidance for the Full-Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.2% to US$26.37

New major risk - Revenue and earnings growth

Nevro Corp. to Report Q3, 2023 Results on Nov 01, 2023

Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold

Nevro Corp. Announces New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy

Nevro Announces Launch of HFX Connect in Europe and CE Marking of Expanded Labelling for the HFX SCS system

Consensus EPS estimates fall by 16%

Nevro Corp. Revises Earnings Guidance for the Full-Year 2023

New minor risk - Shareholder dilution

Price target decreased by 23% to US$28.80

Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?

Price target decreased by 8.5% to US$37.57

Independent Director recently bought US$172k worth of stock

Price target decreased by 8.5% to US$38.43

Nevro Corp. Announces Executive Changes

Nevro Corp. to Report Q2, 2023 Results on Aug 01, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Independent Lead Director exercised options to buy US$2.9m worth of stock.

Investors Shouldn't Be Too Comfortable With Nevro's (NYSE:NVRO) Robust Earnings

Nevro falls to 52-week low; down ~49% over last year

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Nevro: Treating Patient Back Pains, Causing Shareholder Back Pains

Nevro Corp. to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society 26th Annual Meeting

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Consensus forecasts updated

Nevro Corp. to Report Q4, 2022 Results on Feb 16, 2023

Nevro: Opportunity Overshadowed By Weaknesses

Price target decreased to US$47.73

Consensus forecasts updated

Price target decreased to US$50.36

Nevro Corp. Updates Earnings Guidance for the Year Ending December 31, 2022

Boston Scientific drives rival Nevro lower after remarks on neuromodulation

Price target decreased to US$53.91

Nevro Corp. Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain

Nevro's Senza spinal cord stimulation system for chronic pain gets FDA approval

Nevro Corp. to Report Q3, 2022 Results on Nov 02, 2022

Nevro gets FDA approval for Costa Rica manufacturing operations